(Q33901316)

English

Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Long-term clinical outcomes of a phase I trial of intravesical docetaxel in the management of non-muscle-invasive bladder cancer refractory to standard intravesical therapy (English)

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

phase I clinical trial

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

author name string

Melissa A Laudano

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Lamont J Barlow

2

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Alana M Murphy

3

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Daniel P Petrylak

4

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Manisha Desai

5

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Mitchell C Benson

6

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

James M McKiernan

7

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

language of work or name

0 references

publication date

13 November 2009

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

75

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

1

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

134-137

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Cancer statistics, 2008

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5508734

5 July 2018

Long-term results and complications of intracavitary bacillus Calmette-Guerin therapy for bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5508734

5 July 2018

Superficial bladder tumors (stage pTa, grades 1 and 2): the importance of recurrence pattern following initial resection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5508734

5 July 2018

Bacillus Calmette-Guerin immunotherapy for bladder cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5508734

5 July 2018

Bacillus Calmette-Guerin therapy for superficial bladder cancer: a 10-year followup

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5508734

5 July 2018

Superficial bladder cancer: progression and recurrence

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.112

7 January 2021

Treatment of high-risk superficial bladder cancer with maintenance bacille Calmette-Guérin therapy: preliminary results

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.112

7 January 2021

Phase I trial of intravesical docetaxel in the management of superficial bladder cancer refractory to standard intravesical therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.112

7 January 2021

Taxol and taxotere in bladder cancer: in vitro activity and urine stability

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.112

7 January 2021

Risks and benefits of repeated courses of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.112

7 January 2021

Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2009.06.112

7 January 2021

5-year followup of a randomized prospective study comparing mitomycin C and bacillus Calmette-Guerin in patients with superficial bladder carcinoma. Swedish-Norwegian Bladder Cancer Study Group

1 reference

https://pubmed.ncbi.nlm.nih.gov/19913890

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.UROLOGY.2009.06.112

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

29 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33901316&oldid=1749482082"